The data from the pivotal XTEND-1 Phase 3 study published in NEJM show that efanesoctocog alfa met primary and key secondary endpoints, demonstrating clinically meaningful prevention of bleeds and superior bleed protection compared to prior factor VIII prophylaxis based on an intra-patient comparison. The data show that efanesoctocog alfa can offer patients increased bleed protection, leading to improved outcomes, such as reduced pain and improved physical functioning, that may impact daily life with a redu c ed treatment burden. Based on th e XTEND-1 study results assessing efanesoctocog alfa, we have the oppor tun ity to provide near normal factor activity levels for an extended period of time ( the majority of a week ) with a single dose, which is a first for hemophilia A. Currently, they often need to make trade - offs between bleed protection and dosing frequency. The severity of hemophilia is determined by the level of clotting factor activity in a person’s blood.Īngela Weyand, MD Investigator of the XTEND-1 Clinical Trial and Associate Professor at Michigan Medicine “ We are excited about the potential for efa nesoctoco g alfa to address unmet needs by allow ing people living with hemophilia to enjoy an active lifestyle. Hemophilia A is a rare, lifelong condition in which the ability of a person’s blood to clot properly is impaired, leading to excessive bleeds that can result in joint damage and chronic pain, and potentially impact their quality of life. Efanesoctocog alfa is currently under priority review by the United States Food and Drug Administration (FDA) and the target action date for the decision is February 28, 2023. These data demonstrate that efanesoctocog alfa delivered normal to near-normal factor activity levels (>40%) for the majority of the week with once-weekly dosing. P aris and Stockholm – January 25, 202 3 – Pivotal study data published in T he New England Journal of Medicine (NEJM) continues to highlight the efficacy, safety, and pharmacokinetic profile of efanesoctocog alfa, an investigational treatment for hemophilia A. How to publish with us, including Open Access Journal metrics 5.7 (2022) Impact factor 6.NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A With our rigorous and swift peer review process, the journal is highly rated by authors, with over 80% reporting an excellent or good publishing experience with us.The journal publishes practice-based evidence to support evidence-based practice, in internal medicine, primary care and hospital medicine.Highly accessible through SpringerLink, we publish to a broad audience, recording over 2.9 million article downloads in 2021. We are the official journal of the Society of General Internal Medicine, received by all Society members and ranked #1 in the Google Scholar H-5 Index of Primary Health Care.JGIM is ranked #1 in the Google Scholar H-5 Index of Primary Health Care, with a 2019 H-5 Index of 57. Its articles focus on topics such as clinical medicine, epidemiology, prevention, health care delivery, curriculum development, and numerous other non-traditional themes, in addition to classic clinical research on problems in internal medicine. It promotes improved patient care, research, and education in primary care, general internal medicine, and hospital medicine. The Journal of General Internal Medicine is the official journal of the Society of General Internal Medicine.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |